Harvard Bioscience, Inc.

Equities

HBIO

US4169061052

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 02:13:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3.645 ^USD	+0.69%		-1.62%	-31.96%

Apr. 09	Harvard Bioscience Reducing Headcount	MT
Apr. 09	Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth	CI

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

April 09, 2024 at 09:00 am EDT

Harvard Bioscience, Inc. announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million.

Latest news about Harvard Bioscience, Inc.

Harvard Bioscience Reducing Headcount	Apr. 09	MT
Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth	Apr. 09	CI
Harvard Bioscience, Inc. Enters into A Third Amendment to the Credit Agreement	Apr. 03	CI
Transcript : Harvard Bioscience, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q4 Revenue $28.2M	Mar. 07	MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q4 EPS $0.04	Mar. 07	MT
Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024	Mar. 07	CI
Harvard Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting	Mar. 06	CI
Transcript : Harvard Bioscience, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q3 Revenue $25.4M	Nov. 07	MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q3 EPS $0.01	Nov. 07	MT
HARVARD BIOSCIENCE INC - REMAIN ON PATH TO REDUCING NET LEVERAGE…	Nov. 07	RE
Harvard Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023	Nov. 07	CI
Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference	Nov. 06	CI
Harvard Bioscience Unit Named as Exclusive Distributor of Etisense's Cardiorespiratory Monitoring Product	23-09-18	MT
Insider Buy: Harvard Bioscience	23-08-21	MT
Harvard Bioscience Seeks Acquisitions	23-08-08	CI
Transcript : Harvard Bioscience, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q2 EPS $0.04, vs. Street Est of $0.06	23-08-08	MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q2 Revenue $28.8M, vs. Street Est of $29.5M	23-08-08	MT
Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023	23-08-08	CI
Harvard Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI

Chart Harvard Bioscience, Inc.

Duration

Period

More charts

Company Profile

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Harvard Bioscience, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.62 USD

Average target price

7 USD

Spread / Average Target

+93.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
HARVARD BIOSCIENCE, INC.	-31.96%	157M
THERMO FISHER SCIENTIFIC	+8.61%	219B
DANAHER CORPORATION	+7.02%	183B
INTUITIVE SURGICAL, INC.	+10.90%	133B
BOSTON SCIENTIFIC CORPORATION	+24.95%	108B
SIEMENS HEALTHINEERS AG	+0.27%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+12.76%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.96%	48.2B
AGILENT TECHNOLOGIES, INC.	+0.29%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+13.56%	39.35B

Other Advanced Medical Equipment & Technology